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Key messages
What is already known about this subject?
 ► Mutations in the Norrie disease (ND) gene are sus-
pected to be related to advanced retinopathy of pre-
maturity (ROP) development.
 ► Previous studies have shown inconsistent results 
regarding the mutations in the ND gene and the de-
velopment or progression of ROP.
 ► There might be variations in the presence of mu-
tations among different countries in Asia (previous 
studies from Korea and Japan in East Asia, and 
Kuwait as a Middle Eastern Asian country).
What are the new findings?
 ► Mutations in the ND gene (especially in exon 3) play 
minimal to no role in the progression of severe ROP 
given the fact we did not find any polymorphism in 
any of the patients in Indonesia.
How might these results change the focus of 
research or clinical practice?
 ► Our result cannot explain why severe ROP is more 
frequent in Indonesian infants than in infants from 
other racial backgrounds.
 ► Further studies must be conducted to find definitive 
explanations as to why ROP regresses in some pa-
tients, while it progresses in others.
 ► We have studied six gene mutations that are already 
known to be related to the development of ROP and 
no mutation was discovered in any of those genes.
 ► However, it is possible that the development or pro-
gression of ROP might be associated with other mu-
tations in the ND gene beyond what we investigated 
in this study.
AbsTrACT
Objective Retinopathy of prematurity (ROP) is a major 
cause of blindness in newborn infants, which also occurs 
in low-income and middle-income countries. Why ROP 
progresses in some infants while it regresses in others 
is still presently unknown. Studies suggest that genetic 
factors might be involved. Mutations in the Norrie disease 
(ND) gene are suspected to be related to advanced ROP 
development. Indonesia is a country with relatively high 
incidence of ROP, yet the role of these genetic factors in 
the pathogenesis of ROP cases is still unknown. The study 
aimed to investigate the presence of mutations in ND on 
the X chromosome in infants with both non-advanced and 
advanced ROP in Indonesia.
Methods and Analysis This is a case–control study 
of polymorphisms in six variants within the ND gene in 
exon 3, C597A, L108P, R121W, A105T, V60E and C110G, in 
preterm newborn infants in four major hospitals in Greater 
Jakarta, Indonesia.
results We included 162 preterm newborn infants. 
ROP was diagnosed in 83 infants, and 79 infants served 
as controls. Among those with ROP, 57 infants had type 
2, while others had type 1. We did not find any gene 
polymorphisms in any of the infants with ROP nor in the 
control group.
Conclusion We conclude that it is very unlikely that the 
six polymorphisms in exon 3 of the ND gene studied in 
this paper are involved in the development or progression 
of ROP in preterm infants in our population sample in 
Indonesia.
InTrOduCTIOn
Retinopathy of prematurity (ROP) is a major 
cause of blindness in preterm infants. The 
ROP incidence in infants with gestational ages 
of more than 26 weeks has been decreasing in 
developed countries due to improved quality 
of neonatal care. In contrast, an incidence is 
seen in infants born before 26 weeks.1 2 We 
showed that the incidence of ROP is higher 
in preterm infants born in Indonesia as 
compared with developed countries, and 
is also seen in infants with gestational ages 
of up to 34 weeks.3 Our results are in accor-
dance with other studies in low-income and 
middle-income countries.4
ROP is a multifactorial disease. Gestational 
age, birth weight and use of supplemental 
oxygen are known risk factors. In Indo-
nesia, we found that other factors such as 
sepsis, asphyxia, patent ductus arteriosus 
and multiple blood transfusions might also 
play a role.3 However, none of the presently 
identified risk factors can explain why some 
infants develop ROP while others do not. It 
is also not known why ROP regresses in most 
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A number of studies have suggested that genetic factors 
influence the development and severity of ROP.5–14 A 
study of monozygotic and dizygotic twins showed that 
genetic factors accounted for 70% of the variance in 
liability for ROP.5 Cooke et al13 found that a mutation in 
the VEGF gene was related to the progression of ROP 
to threshold levels. Preterm infants who were homozy-
gous for six alleles in the VEGF gene were twice as likely 
to develop threshold ROP.13 Mohamed et al14 studied 
the genetic polymorphisms with candidate genes and 
genes previously genotyped for associations with preterm 
delivery. They found that IHH, AGTR1, TBX5, CETP 
and GP1BA were all associated with the development of 
ROP.14 Most studies described an association of mutations 
in the Norrie disease (ND) gene on the X chromosome 
with the progression of ROP.6–12 However, other studies 
could not confirm these results. ND, familial exudative 
vitreoretinopathy (FEVR) and ROP are retinal diseases 
which share similar phenotypes. ND is caused by a muta-
tion in the Norrie (ND) gene, a condition which leads to 
a deficiency of Norrie protein.15 FEVR is characterised 
by reduced retinal vascularisation, retinal retraction and 
retinal detachment.
There are indications that racial differences exist in the 
development of ROP. Studies have shown a lower inci-
dence of ROP in African–American infants and a higher 
incidence in Asian infants.16 That race might be involved 
in the development and progression of ROP was also 
found in studies in different populations in the USA.17
No study has evaluated if the higher number of ROP 
incidence in Indonesia might be related to the presence 
of mutations in the ND gene. Therefore, we investigated 
if mutations in the ND are present in infants with ROP in 
Indonesia.
MeTHOds
This is a case–control study conducted in four hospi-
tals (Harapan Kita Women and Children Hospital, Budi 
Kemuliaan Hospital, Awal Bros Tangerang Hospital, 
Royal Taruma Hospital) in Greater Jakarta, Indonesia. 
All infants admitted to the neonatal intensive care unit 
of each hospital and screened for ROP were included in 
the study. Most patients came from Jakarta, and the rest 
from West Java, Central Java, Sumatra and Kalimantan. 
Infants with birth weight less than 1500 g and/or gesta-
tional age of less than 32 weeks, and infants with a higher 
birth weight and/or gestational ages who needed respi-
ratory support, were screened for ROP and included in 
this study.
Infants diagnosed with ROP type 2 or type 1, according 
to the Early Treatment for Retinopathy of Prematurity 
criteria,18 were included as patients, while infants without 
ROP were included as controls. A venous blood sample 
or a buccal swab was obtained from each infant.
dnA analysis
The basis of this study were Haider et al’s19 findings in 
2002 that the incidence of AA genotype of the C597A 
polymorphism in the ND gene was considerably higher in 
advanced-stage ROP cases. Therefore six alterations of the 
ND gene were analysed by amplifying the ND gene in the 
third exon using primers from these previous studies.7 19 
We followed the procedure, techniques and primers that 
have been used previously, PCR-RFLP (PCR-restriction 
fragment length polymorphism) for four genetic vari-
ants C597A, L108P, R121W and A105T, and PCR-SSP 
(PCR-single specific primer) for two other variants V60E 
and C110G.7 19–21 DNA sequencing was performed on 36 
samples to verify the results of PCR-RFLP and to detect 
V60E and C110G mutations where the PCR-SSP failed.
We did not use PCR-RFLP for the two additional vari-
ants due to the method and primers used in the findings 
of V60E and C110G polymorphisms in previous studies22 
(Torrente et al21) using PCR-SSP.21 22 This method allows 
gene amplification where only a partial sequence infor-
mation is available even when the information is only 
known at one end of the DNA fragment. We screened 
for six variants all within the same exon because some 
supporting literature states that the majority of mutations 
are seen in the ‘translated region’ in the third exon of 
the ND gene.23–26 Although in subsequent studies other 
gene locations were shown that might be associated with 
ROP, we chose the above-mentioned six genes because 
they were evaluated in most of the studies. In table 1 we 
describe the studies on the relationship between ND 
gene mutations and ROP.
DNA was isolated from the patient’s whole blood, buffy 
coat or buccal swab. DNA isolation was done using Isola-
tion Kit Gene aid protocols. The DNA obtained from 
the PCR (DNA fragment sized 297 base pair [bp]) was 
cut with restriction enzymes to determine the alterations 
in exon 3. HaeIII restriction enzyme was used to detect 
C597A polymorphism and L108P mutation, MspI restric-
tion enzyme for R121W mutation, and MboII restriction 
enzyme for A105T mutation. Subsequently, PCR-RFLP 
results were visualised by electrophoresis. Optimisation 
of PCR-SSP wild-type and mutant primer to detect V60E 
and C110G mutation was carried out using annealing 
temperatures of 50°C–72°C, primer concentrations of 
25 pmol, 30 pmol, 35 pmol and 40 pmol, as well as the 
addition of dimethyl sulfoxide. Optimisation for the wild-
type V60E primer was successfully performed (258 bp). 
The PCR-SSP for wild-type V60E was performed using 
an annealing temperature of 57°C and a primer concen-
tration of 30 pmol or 40 pmol. However, optimisation of 
mutant V60E primer, wild-type and mutant C110G primer 
failed to get the optimal PCR condition. Results for the 
optimisation showed many unspecific bands. Wild-type 
and mutant C110G primer also produced thick dimers. 
Therefore we decided to perform DNA sequencing to 
verify the results of PCR-RFLP and PCR-SSP.
resulTs
A total of 182 infants were enrolled in this study. The 
DNA amplification was performed successfully in 162 
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Exon 3 6 Haider et al,22 
Kuwait
A105T dan Val160Glu 
mutations.
Exon 3
2 Buffen et al,31 
(1999), USA
Mutations at 3’ 
UTR.
Exon 1 7 Haider et al,19 
Kuwait
AA genotype of C597A 
polymorphism.
Exon 3





Exon 3 8 Kim et al,9 
Korea
No gene mutation. 3 exon and their 
flanking areas
4 Talks et al,27 
London, UK
Deletions (one 5 
bp and the other 
71 bp) of the CT 
repeat sequence 
in exon 1 of 
NDP).




Six alterations: 1 in the 5’ 
UTR of exon 2, and 4 in the 
3’ UTR of exon 3, and the 
other 14 bp deletion in the 
5’ UTR of exon 1.
Exons 1, 2, 3, 5’ 
UTR exon 2 and 
3’ UTR exon 3
5 Hiraoka et al,11 
USA
Insertion of an 
additional 12 bp 
CT repeat and 
14 bp deletion in 
exon 1.
3 exons, splice 
sites and the 3’ 
UTR region
10 Hiraoka et 
al,12 Japan
A heterozygous mutation at 
5′ UTR of exon 1 in the ND 
gene and a leucine insertion 
in the signal peptide of 
LRP5.
3 exon and their 
flanking areas
ND, Norrie disease; ROP, retinopathy of prematurity; UTR, untranslated region; bp, base pair.






Total (n) 83 79
Birth weight (g) 1182 (529–2430) 1331 (600–2100)
Gestational age 
(weeks)
30.5 (25–38) 31 (24–35)
Male (%) 38 (45.8) 32 (40.5)
Multiple birth (%) 14 (16.9) 18 (22.8)
Outborn babies (%) 24 (28.9) 23 (29.1)
Low socioeconomic 
status (%)
30 (36.1) 40 (50.6)
Respiratory disorders 
(%)
68 (81.9) 76 (96.2)
ICH/IVH (%) 18 (21.7) 11 (13.9)
BPD (%) 14 (16.9) 10 (12.7)
NEC (%) 13 (15.7) 10 (12.7)
BPD, bronchopulmonary dysplasia; ICH, intracranial hemorrhage; 
IVH, intraventricular hemorrhage; NEC, necrotizing enterocolitis; 
ROP, retinopathy of prematurity.






Type 1 ROP 
(n=26)
Type 2 ROP 
(57)
Birth weight (g) <1000 
(%)
13 (50) 11 (19) 11 (14)
1000–
1500 (%)
13 (50) 34 (59) 46 (58)
>1500 
(%)
0 (0) 12 (21) 22 (28)
Gestational 
age (weeks)
<28 (%) 12 (46) 3 (5) 8 (10)
28–32 (%) 9 (35) 34 (60) 44 (56)
>32 (%) 5 (19) 20 (35) 27 (34)
ROP, retinopathy of prematurity.
samples. The clinical characteristics of the infants are 
presented in table 2.
Birth weight and low socioeconomic status were slightly 
higher (p<0.05) in the control group, while other charac-
teristics were not different between the groups (p>0.05). 
Of the infants with ROP, 24 had a birth weight of less than 
1000 g and 15 a gestational age of less than 28 weeks. 
Forty-seven infants with ROP had a birth weight of 1000–
1500 g and 43 infants a gestational age of 28–32 weeks. 
Twelve infants had a birth weight of more than 1500 g 
and 25 infants had a gestational age of above 32 weeks 
(table 3). Fifty-seven infants showed type 2 ROP, while 26 
showed type 1 (table 3).
The PCR-RFLP process showed that all samples have 
wild-type ND genes (table 4). Mutations or polymorphism 
of C597A, L108P, R121W and A105T were not found in 
any of the samples collected both from infants with ROP 
and the control group.
DNA sequencing was performed on 36 samples to verify 
the results of PCR-RFLP and to detect V60E and C110G 
mutations where the PCR-SSP failed. Samples from 26 
infants with ROP and 10 infants from the control group 
(without ROP) were processed in DNA sequencing. 
Observed sequences were compared with sequences 
in GenBank using the BLAST program. The results of 
BLAST showed 99% homology with Homo sapiens’ ND, 
 o
n





phth: first published as 10.1136/bmjophth-2018-000211 on 27 February 2019. Downloaded from 
4 Siswanto JE, et al. BMJ Open Ophth 2019;4:e000211. doi:10.1136/bmjophth-2018-000211
Open access












Type 1 ROP 
(n=26)




C597A HaeIII CC: 12, 68, 
104, 113 bp
CC 26 57 79
CA: 12, 68, 
104, 113, 172 
bp
CA 0 0 0
297 bp AA: 12, 113, 
172 bp
AA 0 0 0
L108P HaeIII LL: 12, 68, 
104, 113 bp
LL 26 57 79
LP: 12, 30, 
63, 83, 104, 
113 bp
LP 0 0 0
PP: 12, 30, 
68, 83, 104 bp
PP 0 0 0
R121W MspI RR: 58, 72, 
169 bp
RR 26 57 79
RW: 58, 72, 
130, 169 bp
RW 0 0 0
WW: 130, 169 
bp
WW 0 0 0
A105T MboII AA: 297 bp AA 26 57 79
AT: 103, 194, 
297 bp
AT 0 0 0
TT: 103, 194 
bp
LL 0 0 0
V60E Not all optimisations for primers on PCR-SSP can be performed. 
C110G
ND, Norrie disease; PCR-RFLP, PCR-restriction fragment length polymorphism; PCR-SSP, PCR-single specific primer; ROP, retinopathy of 
prematurity; bp, base pair.
RefSeqGene on chromosome X with an access code NG 
009832.1. Furthermore, the sequences were aligned with 
GenBank’s sequences using ClustalW multiple alignment 
program. We found no differences in the arrangement 
of bases compared with the BLAST of the ND gene in 
six mutation sites, that is, C597A, L108P, R121W, A105T, 
V60E and C110G, in either cases or controls, in exon 3 
(table 5).
dIsCussIOn
We did not find any mutations in the ND gene in the 83 
infants with ROP as well as in the 79 infants in the control 
group. This result does not support the hypothesis that 
this gene may be involved in the development or progres-
sion of ROP in infants from Indonesia. Our result cannot 
explain why severe ROP is more frequent in Indonesian 
infants than in infants from other racial backgrounds.
There are two explanations for our findings. First, there 
might be variations in the presence of mutations among 
different countries in Asia. Our results are in line with a 
study from Korea which also found no mutations in the 
Norrie gene in infants with ROP.9 A study from Hiraoka et 
al12 found one infant with a heterozygous mutation in the 
5’ untranslated region (UTR) of exon 1 ND gene in 17 
Japanese infants with advanced ROP and an insertion in 
the signal peptide of LRP5 in another infant.12 In another 
study Hiraoka et al11 failed to find mutations in exons 2 
and 3 and the 3’ UTR of the ND gene. They found in 
100 patients with severe ROP two different mutations in 
exon 1.11 We did not study these mutations because these 
mutations were reported only once. Further studies are 
needed to confirm this possibility.
Second, previous studies have shown inconsistent 
results regarding the mutations in the ND gene and the 
development or progression of ROP.6–8 10 11 19 27 28 Shastry 
et al6 described missense mutations (R121W and L108P) 
in 4 out of 16 infants with stage 4 or 5 ROP. In a follow-up 
study, they found one patient with an insertion in exon 1 
and one with a deletion in the same exon in 100 infants 
with ROP.11 Haider et al7 initially failed to find a rela-
tion between mutations in R121W and L108P in infants 
from Kuwait. Later, he found a polymorphism in the ND 
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Table 5 Multiple alignment results of ND gene sequences 













C597A CC 17 9 10
CA 0 0 0
AA 0 0 0
L108P LL 17 9 10
LP 0 0 0
PP 0 0 0
R121W RR 17 9 10
RW 0 0 0
WW 0 0 0
A105T AA 17 9 10
AT 0 0 0
TT 0 0 0
V60E VV 17 9 10
VG 0 0 0
GG 0 0 0
C110G CC 17 9 10
CG 0 0 0
GG 0 0 0
ND, Norrie disease; ROP, retinopathy of prematurity.
gene C597A in 23 out of 24 infants with advanced stage 
ROP.19 Talks et al27 found two patients with a deletion in 
exon 1 of the ND gene in a group of 22 patients with 
stage 4 or 5 ROP. On the other hand, Dickinson et al10 
found no increased incidence of ND mutations in infants 
with ROP. Hutcheson et al28 found five novel nucleotide 
changes in 143 infants with severe ROP, one in the 5’ 
UTR region of exon 2 and four in the 3’ UTR region 
of exon 3. They concluded that ND gene polymorphism 
might play a role in the pathogenesis of ROP, but does 
not appear to be a major causative factor. Recently, Dailey 
et al8 found an FZD4 gene mutation, instead of mutations 
of the ND gene, to be associated with severe ROP. Hart-
nett29 recently noted a lack of consensus in reports of 
genetic variants associated with ROP, including VEGF, 
EPAS1, SOD and the WNT signalling pathway as well as 
the ND gene. Hartnett et al30 reported a large study of 
two cohorts (817 and 543 infants) of US preterm infants 
with birth weight <1000 g and found an single nucleotide 
polymorphism (SNP) in the BDNF gene that encodes for 
brain-derived neurotrophic factor to be significantly asso-
ciated with severe (threshold) ROP. No mutations in the 
ND gene were found. We also did not find any mutations 
in the ND gene in the infants with ROP.
Finally, DNA sequencing was performed on 36 infants. 
The samples were selected based on a simple random 
sampling method. The purpose of the sequencing was to 
detect polymorphisms in all mutations, including V60E 
and C110G. The χ2 goodness of fit was used to iden-
tify the consistency between the characteristics of the 
36 infants and those of the whole group. All variables 
showed a p value of >0.05, indicating that there were no 
significant differences between these 36 infants and the 
whole group. It can be concluded that the 36 samples are 
representative of the whole group.
A limitation of our study is that we limited the search 
for mutations in the ND gene to mutations that were 
described more than once in the literature. We realise 
that we may have missed mutations, mutations that might 
be found especially in infants in Asia. More studies will be 
needed to screen for more mutations than we did.
Based on our results and previously published studies, 
we conclude that it is very unlikely that the six polymor-
phisms in exon 3 of the ND gene studied in this paper 
are involved in the development or progression of ROP. 
Further studies must be conducted to find definitive 
explanations as to why ROP regresses in some patients, 
while it progresses in others.
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